BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9515812)

  • 1. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
    Gonzalgo ML; Hayashida T; Bender CM; Pao MM; Tsai YC; Gonzales FA; Nguyen HD; Nguyen TT; Jones PA
    Cancer Res; 1998 Mar; 58(6):1245-52. PubMed ID: 9515812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
    Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
    Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer.
    Tsutsumi M; Tsai YC; Gonzalgo ML; Nichols PW; Jones PA
    Oncogene; 1998 Dec; 17(23):3021-7. PubMed ID: 9881704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with its transcriptional regulation in primary lymphomas.
    Malumbres M; Pérez de Castro I; Santos J; Fernández Piqueras J; Pellicer A
    Oncogene; 1999 Jan; 18(2):385-96. PubMed ID: 9927195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
    Bender CM; Pao MM; Jones PA
    Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell division is required for de novo methylation of CpG islands in bladder cancer cells.
    Velicescu M; Weisenberger DJ; Gonzales FA; Tsai YC; Nguyen CT; Jones PA
    Cancer Res; 2002 Apr; 62(8):2378-84. PubMed ID: 11956100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
    Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
    Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.
    Robert MF; Morin S; Beaulieu N; Gauthier F; Chute IC; Barsalou A; MacLeod AR
    Nat Genet; 2003 Jan; 33(1):61-5. PubMed ID: 12496760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing.
    Hamada T; Goto M; Tsutsumida H; Nomoto M; Higashi M; Sugai T; Nakamura S; Yonezawa S
    Cancer Lett; 2005 Sep; 227(2):175-84. PubMed ID: 16112420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
    Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB
    Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development.
    Sakashita K; Koike K; Kinoshita T; Shiohara M; Kamijo T; Taniguchi S; Kubota T
    J Clin Invest; 2001 Oct; 108(8):1195-204. PubMed ID: 11602627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
    Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
    Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denaturing high-performance liquid chromatography (DHPLC) as a reliable high-throughput prescreening method for aberrant promoter methylation in cancer.
    Betz B; Florl AR; Seifert HH; Dall P; Schulz WA; Niederacher D
    Hum Mutat; 2004 Jun; 23(6):612-20. PubMed ID: 15146466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.